NEW DATA ON ARIMIDEX® HERALD ENTRY INTO EARLY BREAST CANCER AstraZeneca today announced that new data presented at the San Antonio Breast Cancer Meeting demonstrate for the first time that leading aromatase inhibitor Arimidex ® is significantly more effective and has important tolerability benefits compared with the current gold standard, tamoxifen, as an adjuvant treatment in postmenopausal women with early breast cancer.
FIRST PHASE II STUDY RESULTS SHOW ANTI-TUMOUR ACTIVITY WITH IRESSA™ IN ADVANCED NON-SMALL CELL LUNG CANCER Preliminary data from the first pivotal phase II trial, presented today at the 12th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Miami, USA , demonstrate that when used as a second or third-line treatment, IRESSA™ leads to overall disease control in more than 50 per cent of unselected  patients with advanced non-small cell lung cancer (NSCLC) who have failed previous platinum-based therapy.
Wednesday, 31 October 2001
ASTRAZENECA WINS GENERIC OMEPRAZOLE CASE IN NORWAY AstraZeneca today announced that the Oslo Byrett (Oslo City Court) in Norway found that a generic omeprazole product marketed by Scandinavian Pharmaceuticals-Generics AB (Scand Pharm) infringes AstraZeneca’s formulation patent for omeprazole, the substance used in Losec. At the same time, the Court declared AstraZeneca’s omeprazole formulation patent valid.
Tuesday, 23 October 2001
PRILOSEC US LITIGATION AstraZeneca today announced that it had received confirmation that its pending litigation to defend its patents associated with Prilosec in the US will go to trial in a case to be heard by Judge Jones commencing in New York on December 5th 2001.
Friday, 19 October 2001
ZD1839 IRESSA DATA AstraZeneca is encouraged by the positive results from IDEAL 1 ( I RESSA D ose E valuation in A dvanced L ung cancer), the first pivotal study of ZD1839 (IRESSA) in non-small-cell-lung-cancer (NSCLC) and looks forward to the presentation of these phase II data at the 12th AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" in Miami, USA. Whilst the abstract of the data is available on www.aacr.org , the full results from IDEAL 1 will not be presented until Thursday,
Tuesday, 9 October 2001
NEXIUM® OUTPERFORMS LANSOPRAZOLE IN FIRST HEAD-TO-HEAD CLINICAL TRIALS Stanhope Gate, London, UK - The long-awaited results of head-to-head clinical trials between AstraZeneca’s newest proton pump inhibitor (PPI) therapy, Nexium® (esomeprazole), and its principal competitor, lansoprazole, were released today at the United European Gastroenterology Week (UEGW) in Amsterdam.
This website is intended for people seeking information on AstraZeneca's International business. We also have national business sites; links to these are under 'Other AZ websites' at the top of the page.